Lilly showcases positive late-stage data in diabetes treatments

pharmafile | June 13, 2016 | News story | Research and Development, Sales and Marketing diabetes, lilly 

Eli Lilly (NYSE: LLY) has presented data on their diabetes drugs in late-stage trials at the 76th American Diabetes Association Scientific Sessions in New Orleands, with Trulicity (dulaglutide) and Tradjenta (linagliptin) providing the pick of the results.

In the Phase III AWARD-9 trial, Trulicity significantly reduces haemoglobin A1c and body weight as an add-on to insulin glargine without increasing the risk of low blood sugar after 28 weeks compared to placebo plus insulin glargine. After 28 weeks of treatment with Trulicity, patients also saw significant reductions in fasting serum glucose levels while also taking less units of insulin glargine while also on Trulicity compared to the placebo plus insulin glargine patients.

Zvonko Milicevic, senior medical fellow at Lilly Diabetes, says: “Despite best efforts to manage their A1C with diet and oral agents, many people with type 2 diabetes transition to injectable therapy as a natural part of the disease progression. For people with type 2 diabetes who are inadequately controlled on insulin glargine alone, AWARD-9 may show that Trulicity is a treatment option that could significantly reduce A1c when used in combination with their current insulin therapy.”

Lilly also announced post-marketing data for Tradjenta, which launched in the US in 2015. Co-marketed by Boehringer Ingelheim, new data shows that the drug reduced blood sugar in adults with type-2 diabetes who are at risk for kidney impairment.

In the MARLINA-T2D trial at 24 weeks, Tradjenta was associated with a significant 0.6 reductio in the blood glucose measure A1c versus plaebo.

Principal trial investigator, Professor Per-Henrik Groop, comments: “Up to half of people with type 2 diabetes experience long-term problems with kidney function. Diabetes treatment options are generally limited for this group. These results support the use of Tradjenta, with just one dose for all patients, including those with type 2 diabetes who have early signs of kidney disease.”

Sean Murray

Related Content


Abbott to acquire Bigfoot Biomedical

Abbott and Bigfoot Biomedical have announced a definitive agreement for Abbott to acquire Bigfoot, however …


First cellular therapy for patients with type 1 diabetes approved by FDA

The US Food and Drug Administration (FDA) has announced that it has approved Lantidra, the …


AstraZeneca’s Xigduo XR approved in China for adults with type-2 diabetes

AstraZeneca has announced that its Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose …

Latest content